Biotech Daily

Thursday August 20, 2026

Daily news on ASX-listed biotechnology companies

*** ASX, BIOTECH UP: CURVEBEAM UP 11%; MEDICAL DEVELOPMENTS DOWN 8%**

*** TELIX REVENUE UP 22% TO $670m; LOSS TURNED TO $54m PROFIT**

*** MEDICAL DEVELOPMENTS REVENUE UP 9% TO $43m; PROFIT UP 566% TO $626k**

*** IDT REVENUE UP 3% TO $21m; LOSS DOWN 66% TO $3m**

*** DIMERIX $14.1m EVEREST DMX-200 LICENCE PAYMENT**

*** MCRI: 'GENE THERAPY RESTORES HEART FUNCTION, IN-VITRO, IN MICE'**

*** WEHI IRON DEFICIENCY FINGER-PRICK BLOOD TEST**

*** MEMPHASYS VIETNAM FELIX REGISTRATION, 1st ORDER RECEIVED**

*** RHYTHM COLOSTAT INCLUDED ON TGA IN-VITRO TEST DATABASE**

*** RADIOPHARM 180mCi PHASE I RAD202 DOSE OKAY**

*** ANTEOTECH, XERABRID BATTERY DEAL**

*** EMYRIA RECRUITS 15 MORE PRESCRIBERS**

*** AUSTRALIAN ETHICAL TAKES 9% OF ONCOSIL**

*** AUSTRALIAN ETHICAL REDUCES TO 7% OF COGSTATE**

*** ARTRYA APPOINTS HELEN KURINCIC DIRECTOR**

*** LITTLE GREEN APPOINTS JENNI PILCHER CFO**

MARKET REPORT

The Australian stock market was up 0.33 percent on Thursday August 20, 2026, with the ASX200 up 30.0 points to 9,083.8 points. Twenty-two of the Biotech Daily Top 40 companies were up, nine fell and nine traded unchanged.

Curvebeam was the best, up 0.2 cents or 11.1 percent to 2.0 cents, with 600,000 shares traded. Dimerix climbed 10.2 percent; Artrya was up 8.6 percent; 4D Medical, Optiscan and Polynovo were up more than six percent; Clarity, Immutep and Mesoblast improved more than five percent; Alcidion, Avita, Clinuvel, Orthocell and Starpharma were up more than four percent; Amplia, EBR, Pro Medicus and Telix climbed more than three percent; Actinogen, CSL, Paradigm, Resmed and Saluda rose more than two percent; with Neuren and Resonance up by more than one percent.

Medical Developments led the falls, down 4.0 cents or 7.8 percent to 47.5 cents, with 266,580 shares traded. Cyclopharm fell 5.1 percent; Nova Eye was down 3.45 percent; Prescient shed 2.5 percent; Nanosonics and Syntara lost more than one percent; with Cochlear, Emvision, Imricor and Racura down by less than one percent.

TELIX PHARMACEUTICALS

Telix says revenue for the six months to June 30, 2026 was up 22.3 percent to $US477,350,000 ($A670,114,000), with last year's $US2,292,000 ($A3,509,000) loss turned to a $US38,330,000 ($A53,891,000) net profit after tax.

Telix said precision medicine revenue from sales of its gallium-68 prostate cancer imaging agents Illuccix and Gozellix rose 10.6 percent to $US388,210,000, "reflecting continued growth in sales volume, pricing and market share gains".

The company said sales from radio-pharmaceutical manufacturing including the acquired RLS Pharmaceuticals, ARTMS and Isotherapeutics rose 8.85 percent to $US83,606,000, with services revenue up 37.8 percent to $US5,111,000.

Telix said its net profit after tax included "$US40 million of other income received from Regeneron and finance costs of $US19 million, predominately related to refinancing of the convertible bonds".

Earlier this year, Telix said it had an up-to $US2.1 billion collaboration with the Tarrytown, New York-based Regeneron for cancer radio-pharmaceutical treatments, with $US40 million up-front (BD: Apr 13, 2026).

Today, Telix managing-director Dr Chris Behrenbruch said the company "delivered an outstanding first half, with strong revenue growth, market share gains and significant progress across clinical and regulatory milestones".

"Our strengthened balance sheet is enabling increased investment in late-stage programs … market expansion opportunities within our precision medicine portfolio and manufacturing and supply chain capabilities that differentiate Telix," Dr Behrenbruch said.

"With multiple near-term catalysts, we enter the second half with strong momentum and confidence," Dr Behrenbruch said.

At its online investor briefing, Telix chief financial officer Darren Smith said that "rather than maximizing near-term returns … we will continue to reinvest our earnings into the business for the remainder of this year and into next year".

"Overall, I believe we are in a strong position, with positive momentum across the business," Dr Behrenbruch said at the briefing.

The company said the US Food and Drug Administration had set a September 11, 2026 Prescription Drug User Fee Act (PDUFA) goal date for its Pixclara glioma brain cancer imaging agent and a European marketing authorization application for the product had been accepted for review.

Telix said a new drug application for Illuccix was under review in China and it was progressing Zircaix for kidney cancer imaging resubmission.

The company said research and development expenditure rose 52.8 percent to $US123,828,000, or 25.9 percent of revenue, compared to 20.9 percent of revenue in the previous corresponding period, "predominantly focused on advancing clinical trials for late-stage therapeutic assets and progressing regulatory resubmissions".

Telix said it expected revenue and other income for the year to December 31, 2026 to be "in excess of $US1.0 billion, with revenue progressing in line with upper end of 2025-'26 guidance of $US950 million to $US970 million".

The company said it "reaffirmed [research and development] expenditure guidance of $US230 million to $US270 million, enabled by the company's strong … performance".

Telix said it had diluted earnings per share of 11.30 US cents compared to last year's diluted loss per share of 0.68 US cents, with negative net tangible assets per share up 21.4 percent to negative 83.00 US cents.

The company said it held cash of $US251,910,000 at June 30, 2026 compared to $US207,156,000 at June 30, 2025.

Telix was up 54 cents or 3.2 percent to $17.38 with 5.6 million shares traded.

MEDICAL DEVELOPMENTS INTERNATIONAL

Medical Developments says revenue for the year to June 30, 2025 rose 9.0 percent to $42,568,000, with net profit after tax up 566.0 percent to $626,000.
Medical Developments said revenue for its Penthrox inhaled methoxyflurane analgesic and other pain management products rose 20.7 percent to $31,620,000, with sales of its respiratory products, including asthma spacers, down 14.9 percent to $10,948,000.
The company said revenue "benefitted from stronger Penthrox demand in all regions and higher Penthrox pricing in Australia".
Medical Developments said that average selling prices in Europe were lower, following transition to partner supply in France and Switzerland and that "the impact of lower demand in the respiratory business was mostly offset by the refund of tariffs paid in respect of imports into the US in 2024-'25 and 2025-'26".
The company said the "impact to earnings of Middle East supply chain disruption and US tariffs remains uncertain and continues to be monitored".
Medical Developments said diluted earnings per share rose 562.5 percent to 0.53 cents, with net tangible asset backing per share up 4.1 percent to 30.7 cents.
The company said that it had cash and cash equivalents of $14,368,000 at June 30, 2026 compared to $17,837,000 at June 30, 2025.
Medical Developments fell four cents or 7.8 percent to 47.5 cents.

IDT AUSTRALIA

IDT says revenue for the year to June 30, 2026 was up 3.4 percent to $20,534,000, with net loss after tax down 66.3 percent to $2,717,000.
IDT said revenue was from its manufacturing services, with active pharmaceutical ingredient production up 29 percent to $5.4 million and solid oral products manufacture up 52 percent to $5.5 million, "capitalizing on opportunities in radio-pharmaceuticals as it continues to service the demand for medicinal cannabis and psychedelic drugs".
The company said advanced therapies revenue fell 11 percent to $5.9 million, which "largely reflects the timing of contracts, not underlying demand, and the outlook for this business is very strong" due to the increasing demand for messenger (m)RNA drugs.
IDT said it was "on track to deliver positive operating earnings in 2026-'27".
The company said diluted loss per share fell 64.55 percent to 0.67 cents, with net tangible assets per share down 12.4 percent to 4.46 cents.
IDT said that it had cash and cash equivalents of $2,515,000 at June 30, 2026 compared to $503,000 at June 30, 2025.
IDT was up 0.4 cents or 10 percent to 4.4 cents with 1.1 million shares traded.

DIMERIX

Dimerix says it has received the $US10 million ($A14.1 million) up-front payment from Hong Kong's Everest Medicines under its DMX-200 licence agreement.
In June, Dimerix said it had an up-to $481 million licence agreement for its DMX-200 for focal segmental glomerulo-sclerosis (FSGS) with Everest (BD: Jun 16, 2026).
At the time, Dimerix managing-director Dr Nina Webster told Biotech Daily that the company would receive an up-front $US10 million within 45 days.
Today, the company said it continued to pursue additional licencing opportunities in territories that remained unpartnered as it advanced DMX-200 towards potential registration and commercialization.
Dimerix was up three cents or 10.2 percent to 32.5 cents with 2.9 million shares traded.

MURDOCH CHILDREN'S RESEARCH INSTITUTE

The Murdoch Children's Research Institute says its gene therapy restores heart function in children with genetic heart disease, sparing the need for transplants.

The Murdoch Children's Research Institute said researchers found that "delivering the ALPK3 gene in a single injection reversed heart muscle disease in [laboratory]-grown patient heart tissue and mouse models".

The Institute said variants in the alpha-protein kinase 3 (ALPK3) gene could "cause cardio-myopathy, affecting the heart's ability to pump blood around the body" leading to enlarged hearts with weak and irregular heartbeats.

MCRI said the study found the adeno-associated virus (AAV) mediated gene therapy might help correct other genetic heart diseases, "not just ones caused by ALPK3 variants, such as those impacted by the [myosin heavy chain 7] gene and [titin] truncating variants, the most common genetic cause of dilated cardio-myopathy".

The Institute said the study, titled 'Alpha protein kinase 3 gene therapy restores heart function in mouse and human models of cardiomyopathy' was published in Nature Cardiovascular Research at: https://www.nature.com/articles/s44161-026-00843-1.

MCRI said the study was "a major step towards a cure for genetic heart diseases, which would spare children from needing heart transplants, surgical or catheter-based procedures, long-term medication use and wearing implantable devices".

The Institute said it was supported by grants from the National Health and Medical Research Council of Australia in collaboration with the Royal Children's Hospital, the University of Melbourne, Monash University, Dynomics Inc, Queensland University of Technology and the Queensland Institute of Medical Research (QIMR) Berghofer.

MCRI's Prof Enzo Porrello said further safety studies were needed before human trials and the researchers were "seeking commercial partners to take this gene therapy into human clinical trials".

WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH

The Walter and Eliza Hall Institute says its finger-prick blood test can detect iron deficiency in minutes, overcoming key limitations of existing point-of-care diagnostics.

WEHI said that the test used a finger-prick blood sample and delivered "accurate results at the point-of-care in a single visit, eliminating the need for specialized laboratory equipment while enabling rapid, convenient diagnosis".

The Institute said the test was developed to "be administered by a broad range of healthcare professionals, removing the need for dedicated training that can be hard to deliver in remote or under-resourced communities".

WEHI said the test closely matched the accuracy of standard laboratory ferritin measurements allowing it to provide "a reliable diagnosis without the need for a follow-up venous blood test, potentially improving access to timely diagnosis and treatment in remote and low-resource settings where laboratory services may be limited".

The Institute said its ferritin test would support both accurate diagnosis and ongoing monitoring, with researchers "now evaluating the test in Sub-Saharan Africa with the goal of establishing it as the region's first validated point-of-care test for iron deficiency".

WEHI said the test was being contract-manufactured under the relevant international industry standards before deployment in Malawi and Kenya to show real-world performance, generate critical evidence and establish a pathway for rapid implementation in low-resource settings.

WEHI's Dr Emily Eriksson said "the diagnostic could become a scalable solution for countries where access to laboratory testing and iron infusions is limited".

MEMPHASYS

Memphasys says it Felix sperm separation device for in-vitro fertilization has been registered in Vietnam, triggering first commercial orders from its distributor TMSC.
Earlier this year, Memphasys said it had a $530,000, two-year contract for its Felix system with Hanoi's TMSC Viet Nam Medical Technology Company (BD: Jun 1, 2026).
Today, the company said it had the first commercial order of 600 Felix cartridges from TMSC following approval, in addition to the 100 cartridges and three consoles previously supplied to support testing, product introduction and preparation for the launch.
Memphasys said TMSC Vietnam had advised that "its early engagement with fertility clinics over the past three weeks has resulted in the first successful pregnancy reported following the use of Felix by a client clinic in Vietnam".
The company said the result was "an encouraging milestone as TMSC Vietnam moves from market preparation into broader commercial introduction".
Memphasys said it would "continue to support training, product education and selected clinic engagement as the commercial rollout progresses".
The company said achieving registration on schedule, beginning the first 600-cartridge commercial order and first reported pregnancy following use of Felix showed "tangible progress against the Vietnam market-entry plan outlined in June 2026".
Memphasys was up 0.05 cents or 8.3 percent to 0.65 cents with two million shares traded.

RHYTHM BIOSCIENCES

Rhythm says its Colostat colorectal cancer blood test has been included in the Australian Therapeutic Goods Administration in-house in-vitro diagnostic notification database.
Rhythm said the inclusion marked "a further regulatory and compliance milestone supporting the Australian commercial rollout of Colostat".
Earlier this year, the company said it had its first commercial sale of Colostat; and 4Cyte Pathology had 38 East Coast Australia blood collection sites (BD: Mar 11, 18, 2026).
Today, Rhythm said Colostat was available at clinical software platform Medicaldirector, with collection-site coverage expanding across the Eastern states.
Rhythm managing-director Dr David Atkins said these were "practical but important milestones in the commercial rollout… [with the focus] shifting from establishing the infrastructure … towards driving clinician engagement, patient access and test utilization".
Rhythm was up 0.6 cents or 7.3 percent to 8.8 cents.

RADIOPHARM THERANOSTICS

Radiopharm says it has data safety and monitoring committee approval to advance to a higher dose level of 180 millicuries (mCi) of RAD202 in its 35-patient, phase I trial.
Last year, Radiopharm said that it had dosed the first of up-to 35 patients in its phase I, dose-escalation trial of lutetium-177 RAD202 for human epidermal growth factor receptor-2 (HER-2)-expressing advanced cancers; and later said it had a positive recommendation to advance to 75 mCi of RAD202 in its 35-patient, phase I trial (BD: Jun 3, Oct 1, 2025).
Today, Radiopharm managing-director Riccardo Canevari said beginning the fourth cohort was a "significant step forward in the development of one of our most promising therapeutic candidates … [and] as we execute on our clinical development strategy, we remain focused on unlocking the full potential of RAD202 and generating meaningful data that could support a differentiated radio-therapeutic option for HER2-positive patients in need of new treatment alternatives".
Radiopharm fell 0.2 cents or 16.7 percent to one cent with 107.9 million shares traded.

ANTEOTECH

Anteotech says it has a collaboration and sales agreement with South Korea's Xerabrid Corp to combine its Anteo S with Xerabrid's ceramic coated separator.
Earlier this year, Anteotech said it would combine its Anteo S battery additive with South Korea's Xerabrid Corp's ceramic coated separator technology (BD: May 26, 2026).
At the time, the company said its Anteo S was designed to improve ceramic coated separator mechanical and thermal stability, improving battery safety and could be used across a wide range of battery anode chemistries including high silicon, graphite, silicon composite, lithium sulfur, lithium metal and sodium-ion.
Anteotech said that potential customers wanted "to reduce overall separator thickness to maximize battery energy density while maintaining thermal stability and battery safety".
"Thinner separators allow more space within the battery for active electrode material, which can increase the battery's energy storage capacity," the company said.
"Improved separator performance can also support the fast charge and discharge rates required in next-generation battery applications," Anteotech said.
The company said that one customer had requested a 1,000-metre-long roll for prototyping and pre-commercial scale trials, potential customers including defence sector electric vertical take-off and landing and drone battery manufacturers; consumer electronic battery manufacturers; super-capacitor manufacturers for high-performance applications; and consumer electronic devices.
Today, Anteotech said the specific commercial terms of the agreement were confidential.
Anteotech fell 0.1 cents or five percent to 1.9 cents with 94.3 million shares traded.

EMYRIA

Emyria says it has recruited 15 additional therapists who have begun training in Perth, with 13 of the recruits meeting revised Therapeutic Goods Administration requirements.
In 2024, Emyria said it opened a Perth Empax Centre evaluating 3,4 methylene-dioxymeth-amphetamine (MDMA) therapy and later said it had Perth, Brisbane and Mornington centres (BD: Apr 10, 2024; Apr 14, Jul 29, 2025; Mar 24, 2026).
In April, the company said it would open a clinic for MDMA-assisted therapy at Matilda Healthcare's Nepean Private Hospital in New South Wales (NSW) (BD: Apr 29, 2026).
Today, Emyria said it had faced authorized prescriber capacity constraints at its Perth and Queensland Empax operations and that the recruits would remove "a key operational bottleneck that had been an impediment to uplifting further clinical activity".
In May, the company said the TGA had expanded the range of clinicians allowed to administer psychedelic-assisted psychotherapy (BD: May 28, 2026).
Emyria was up 0.3 cents or 6.8 percent to 4.7 cents with one million shares traded.

ONCOSIL MEDICAL

Sydney's Australian Ethical says it has increased its substantial shareholding in Oncosil from 2,579,191 shares (8.35%) to 2,913,919 shares (9.43%).
Australian Ethical said that it bought shares between July 29 and August 18, 2026, with the single largest purchase 150,000 shares on August 17, 2026 for $179,441, or $1.20 a share.
Last year, Oncosil said it completed its 400-to-one stock consolidation and at the time had 14,224,271 post-consolidation shares on issue (BD: Jun 6, 2025).
Oncosil was up three cents or 2.6 percent to $1.18.

COGSTATE

Sydney's Australian Ethical says it has reduced its substantial shareholding in Cogstate from 13,583,230 shares (8.00%) to 11,389,497 shares (6.70%).
Australian Ethical said that it bought and sold shares between July 8 and August 18, 2026, with the single largest sale 716,423 shares on August 14 for $1,981,441, or $3.96 a share.
Cogstate was up 15 cents or 5.1 percent to $3.08 with one million shares traded.

ARTRYA

Artrya says it has appointed Helen Kurincic as a non-executive director, effective from August 20, 2026.
Artrya said Ms Kurincic had been Benetas chief executive officer and Heart Care Victoria chief executive officer, a director and chief operating officer of Genesiscare, Integral Diagnostics chair and a director at Estia Health, Sirtex Medical, DCA Group and HBF Health and was currently McMillan Shakespeare chair and a director of Ramsay Healthcare.
The company said Ms Kurincic held a Master of Business Administration from Victoria University.
Artrya was up 40 cents or 8.6 percent to $5.05 with 956,992 shares traded.

LITTLE GREEN PHARMA

Little Green says it has appointed former Cann managing-director Jenni Pilcher as its chief financial officer, effective from August 24, 2026.
Little Green said Ms Pilcher had previously held chief financial officer roles at "a number of ASX-listed life sciences and technology businesses".
Earlier this year, Cann said Ms Pilcher had resigned as managing-director, with chair Mike Ryan appointed interim executive chair (BD: May 5, 2026).
According to her Linkedin page Ms Pilcher held a Bachelor of Business from Auckland, New Zealand's Massey University.
Little Green fell 0.1 cents or 1.4 percent to 7.2 cents.